<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD006932.pub3" GROUP_ID="GYNAECA" ID="592107021515444855" MERGED_FROM="" MODIFIED="2016-09-21 14:29:23 +0100" MODIFIED_BY="Tracey Harrison" REVIEW_NO="L008" REVMAN_SUB_VERSION="5.2.3 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="7.0">
<COVER_SHEET MODIFIED="2016-09-21 14:29:21 +0100" MODIFIED_BY="Tracey Harrison">
<TITLE MODIFIED="2010-01-21 15:06:52 +0000" MODIFIED_BY="[Empty name]">Pharmacological treatment of depression in patients with a primary brain tumour</TITLE>
<CONTACT MODIFIED="2016-09-21 14:29:21 +0100" MODIFIED_BY="Tracey Harrison"><PERSON ID="A0C5FF2882E26AA2003ED3F580915974" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Alasdair</FIRST_NAME><MIDDLE_INITIALS>G</MIDDLE_INITIALS><LAST_NAME>Rooney</LAST_NAME><POSITION>Neuro-Oncology Research Fellow</POSITION><EMAIL_1>ally.rooney@ed.ac.uk</EMAIL_1><EMAIL_2>ally.rooney@ed.ac.uk</EMAIL_2><MOBILE_PHONE>07775802136</MOBILE_PHONE><ADDRESS><DEPARTMENT>Edinburgh Centre for Neuro-Oncology (ECNO)</DEPARTMENT><ORGANISATION>Western General Hospital</ORGANISATION><ADDRESS_1>Crewe Road South</ADDRESS_1><CITY>Edinburgh</CITY><ZIP>EH4 2XU</ZIP><REGION>Scotland</REGION><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 (0)1315372088</PHONE_1><FAX_1>+44 (0)1315371132</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2016-09-21 14:29:21 +0100" MODIFIED_BY="Tracey Harrison"><PERSON ID="A0C5FF2882E26AA2003ED3F580915974" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Alasdair</FIRST_NAME><MIDDLE_INITIALS>G</MIDDLE_INITIALS><LAST_NAME>Rooney</LAST_NAME><POSITION>Neuro-Oncology Research Fellow</POSITION><EMAIL_1>ally.rooney@ed.ac.uk</EMAIL_1><EMAIL_2>ally.rooney@ed.ac.uk</EMAIL_2><MOBILE_PHONE>07775802136</MOBILE_PHONE><ADDRESS><DEPARTMENT>Edinburgh Centre for Neuro-Oncology (ECNO)</DEPARTMENT><ORGANISATION>Western General Hospital</ORGANISATION><ADDRESS_1>Crewe Road South</ADDRESS_1><CITY>Edinburgh</CITY><ZIP>EH4 2XU</ZIP><REGION>Scotland</REGION><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 (0)1315372088</PHONE_1><FAX_1>+44 (0)1315371132</FAX_1></ADDRESS></PERSON><PERSON ID="7538" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Robin</FIRST_NAME><LAST_NAME>Grant</LAST_NAME><POSITION>Consultant Neurologist</POSITION><EMAIL_1>robin.grant7@gmail.com</EMAIL_1><EMAIL_2>Robin.Grant@nhslothian.scot.nhs.uk</EMAIL_2><ADDRESS><DEPARTMENT>Edinburgh Centre for Neuro-Oncology (ECNO)</DEPARTMENT><ORGANISATION>Western General Hospital</ORGANISATION><ADDRESS_1>Crewe Road</ADDRESS_1><CITY>Edinburgh</CITY><ZIP>EH4 2XU</ZIP><REGION>Scotland</REGION><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 131 537 2088</PHONE_1><PHONE_2>+44 131 537 2084</PHONE_2><FAX_1>+44 131 537 2561</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2015-02-11 12:42:48 +0000" MODIFIED_BY="Tracey Bishop">
<UP_TO_DATE>
<DATE DAY="29" MONTH="4" YEAR="2013"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="26" MONTH="10" YEAR="2012"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="29" MONTH="4" YEAR="2015"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="2008"/>
<REVIEW_PUBLISHED ISSUE="3" YEAR="2010"/>
<LAST_CITATION_ISSUE ISSUE="5" YEAR="2013"/>
</DATES>
<WHATS_NEW MODIFIED="2016-09-21 14:29:21 +0100" MODIFIED_BY="Tracey Harrison"><WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2016-09-21 14:29:21 +0100" MODIFIED_BY="Tracey Harrison"><DATE DAY="21" MONTH="9" YEAR="2016"/><DESCRIPTION><P>Contact details updated.</P></DESCRIPTION></WHATS_NEW_ENTRY>


</WHATS_NEW>
<HISTORY MODIFIED="2016-09-21 14:29:21 +0100" MODIFIED_BY="Tracey Harrison"><WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2016-09-21 14:29:21 +0100" MODIFIED_BY="Tracey Harrison"><DATE DAY="11" MONTH="2" YEAR="2015"/><DESCRIPTION><P>Contact details updated.</P></DESCRIPTION></WHATS_NEW_ENTRY><WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2015-02-11 12:42:48 +0000" MODIFIED_BY="Tracey Bishop"><DATE DAY="27" MONTH="3" YEAR="2014"/><DESCRIPTION><P>Contact details updated.</P></DESCRIPTION></WHATS_NEW_ENTRY><WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2014-03-27 12:02:04 +0000" MODIFIED_BY="Tracey Bishop">
<DATE DAY="7" MONTH="4" YEAR="2013"/>
<DESCRIPTION>
<P>Text updated. One new study added to excluded studies (<LINK REF="STD-Caudill-2011" TYPE="STUDY">Caudill 2011</LINK>). The update has not altered the conclusions from the last publication of this review.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY><WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2014-03-27 12:02:04 +0000" MODIFIED_BY="Tracey Bishop">
<DATE DAY="26" MONTH="10" YEAR="2012"/>
<DESCRIPTION>
<P>Updated search of MEDLINE, EMBASE, CENTRAL and PsycINFO. </P>
</DESCRIPTION>
</WHATS_NEW_ENTRY></HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2013-04-10 13:37:00 +0100" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES MODIFIED="2013-04-10 13:37:00 +0100" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2009-09-10 13:24:39 +0100" MODIFIED_BY="[Empty name]">
<NAME>NHS Lothian Neuro-oncology Endowment Fund</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION>
<P>Salary for AR</P>
</DESCRIPTION>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2013-04-29 12:58:51 +0100" MODIFIED_BY="Gail Quinn">
<SUMMARY MODIFIED="2013-04-25 11:44:07 +0100" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2010-02-05 08:38:14 +0000" MODIFIED_BY="[Empty name]">Pharmacological treatment of depression in patients with a primary brain tumour</TITLE>
<SUMMARY_BODY MODIFIED="2013-04-25 11:44:07 +0100" MODIFIED_BY="[Empty name]">
<P>People with brain tumours may experience epilepsy, memory problems and fatigue. Depression is also common and doctors might choose to treat this with antidepressants, since antidepressants are thought to be effective in other patients. However, antidepressants could be less effective, or could cause more side effects, in patients with brain tumours.</P>
<P>The review authors researched whether any drugs have been proven to be effective, and whether they cause significant side effects when prescribed to treat depression in patients with brain tumours. They searched the medical journal literature to find high-quality studies comparing the effectiveness of any one drug treatment for depression in patients with a brain tumour against another treatment. Despite a thorough search, the authors could not find any studies and so cannot determine whether any drug is of any benefit. The review authors conclude that it is important to research whether drugs can treat depression safely and effectively in people with brain tumours.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2013-04-29 12:57:29 +0100" MODIFIED_BY="Gail Quinn">
<ABS_BACKGROUND MODIFIED="2013-04-25 11:44:07 +0100" MODIFIED_BY="[Empty name]">
<P>This is an updated version of the original Cochrane review published in Issue 3, 2010.</P>
<P>Patients with a primary brain tumour often experience depression, for which drug treatment may be prescribed. However, these patients are also at high risk of epileptic seizures, cognitive impairment and fatigue, all of which are potential side effects of antidepressants. The benefit, or harm, of pharmacological treatment of depression in brain tumour patients is unclear.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2010-02-08 11:24:02 +0000" MODIFIED_BY="Gail Quinn">
<P>To assess the benefits and harms of pharmacological treatment of depression in patients with a primary brain tumour.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2013-04-29 12:57:29 +0100" MODIFIED_BY="Gail Quinn">
<P>We updated the search to include the Cochrane Central Register of Controlled Trials (CENTRAL) (<I>The Cochrane Library</I> 2012, Issue 10), MEDLINE to October 2012, EMBASE to October 2012 and PsycINFO to October 2012. We searched the British Nursing Index, LILACS, PSYNDEX, the NHS National Research Register, the NHS Centre for Reviews and Dissemination's Database of Abstracts of Reviews of Effectiveness (DARE) and Web of Knowledge (covering Science Scisearch, Social Sciences Citation Index and Biological Abstracts) for the original review (to July 2009). In the original review we also handsearched <I>Neuro-oncology</I>, the <I>Journal of Neuro-oncology</I>, the <I>Journal of Neurology</I>, <I>Neurosurgery and Psychiatry</I> and the <I>Journal of Clinical Oncology</I> (July 1999 to June 2009) and wrote to all the pharmaceutical companies manufacturing antidepressants for use in the UK.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2013-04-10 13:30:17 +0100" MODIFIED_BY="[Empty name]">
<P>We searched for all randomised controlled trials (RCTs), controlled clinical trials, cohort studies and case-control studies of any pharmacological treatment of depression in patients with a histologically diagnosed primary brain tumour.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2013-04-10 13:30:03 +0100" MODIFIED_BY="[Empty name]">
<P>No studies met the inclusion criteria.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2013-04-07 13:00:02 +0100" MODIFIED_BY="[Empty name]">
<P>We found no eligible studies evaluating the benefits of any pharmacological treatment of depression in brain tumour patients. </P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2013-04-25 11:44:07 +0100" MODIFIED_BY="[Empty name]">
<P>No high-quality studies have examined the value of pharmacological treatment of depression in patients with a primary brain tumour. RCTs and detailed prospective studies are required to inform the effective pharmacological treatment of this common and important complication of brain tumours. Since the last version of this review none of the new relevant studies have provided additional information to change these conclusions.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2013-04-29 12:58:51 +0100" MODIFIED_BY="Gail Quinn">
<BACKGROUND MODIFIED="2013-04-25 11:48:33 +0100" MODIFIED_BY="Gail Quinn">
<SUBSECTION>
<HEADING LEVEL="2">Primary brain tumours</HEADING>
<P>This review is an update of a previously published review in the Cochrane Database of Systematic Reviews (Issue 3, 2010) on 'Pharmacological treatment of depression in patients with a primary brain tumour'.</P>
<P>Primary brain tumours affect around seven in every 100,000 people per year worldwide (<LINK REF="REF-Parkin-2005" TYPE="REFERENCE">Parkin 2005</LINK>). They can be categorised according to World Health Organization (WHO) criteria (<LINK REF="REF-Louis-2007" TYPE="REFERENCE">Louis 2007</LINK>) reflecting their cell of origin and degree of malignancy. The most common kind of primary brain tumour is glioma, a tumour of glial cells (<LINK REF="REF-Wrensch-2002" TYPE="REFERENCE">Wrensch 2002</LINK>). Glioma occurs slightly more frequently in men than women and is more common in the elderly (<LINK REF="REF-Barnholtz_x002d_Sloan-2003" TYPE="REFERENCE">Barnholtz-Sloan 2003</LINK>). Most gliomas (70% to 80%) are 'high-grade' aggressive tumours which significantly reduce patient survival. With current best treatment, roughly one-quarter of adults with the most common type of glioma (glioblastoma multiforme) will survive for two years after diagnosis (<LINK REF="REF-Stupp-2005" TYPE="REFERENCE">Stupp 2005</LINK>).</P>
<P>Around 20% of gliomas are more slowly growing 'low-grade' tumours, associated with a median survival of seven years (<LINK REF="REF-Van-den-Bent-2005" TYPE="REFERENCE">Van den Bent 2005</LINK>). Low-grade gliomas are more frequently associated with epileptic seizures (<LINK REF="REF-Pace-1998" TYPE="REFERENCE">Pace 1998</LINK>). A poorer outcome from low-grade glioma is associated with older age, astrocytoma histology, tumour size &gt; 6 cm and tumour affecting both sides of the brain at presentation (<LINK REF="REF-Pignatti-2002" TYPE="REFERENCE">Pignatti 2002</LINK>).</P>
<P>Meningiomas are another common kind of primary brain tumour, occurring more frequently in women and the elderly, and are often cured by surgery (<LINK REF="REF-Wrensch-2002" TYPE="REFERENCE">Wrensch 2002</LINK>). As a group, primary brain tumours differ from metastatic tumours which spread to the brain from cancer elsewhere in the body.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Depression</HEADING>
<P>Depression is a clinical syndrome of sadness or loss of interest, negative beliefs (for example feelings of guilt or low self esteem) and psychomotor abnormalities (for example fatigue and psychomotor retardation) (<LINK REF="REF-Gelder-2000" TYPE="REFERENCE">Gelder 2000</LINK>). Because some sadness, negative thoughts (for example about loss of health or death) and physical symptoms can be normal in cancer patients, the gold-standard method of diagnosing depression is a structured clinical interview conducted by a specialist in mental health (<LINK REF="REF-APA-2000b" TYPE="REFERENCE">APA 2000b</LINK>; <LINK REF="REF-First-2002" TYPE="REFERENCE">First 2002</LINK>). Significant depressive symptoms can also be identified in patients using rating scales (for example <LINK REF="REF-Zigmond-1968" TYPE="REFERENCE">Zigmond 1968</LINK>) which use cut-off scores to estimate the likelihood of depression and, being easier to administer, are often used as a 'proxy' diagnosis in clinical research.</P>
<P>The reported prevalence of depression in cancer varies depending on the study population, diagnostic method and time at which patients are assessed. Major depression has been reported in up to 27% of systemic cancer patients (<LINK REF="REF-Strong-2007" TYPE="REFERENCE">Strong 2007</LINK>). Those with primary brain tumours may meet diagnostic criteria at least as frequently (<LINK REF="STD-Litofsky-2004" TYPE="STUDY">Litofsky 2004</LINK>; <LINK REF="REF-Wellisch-2002" TYPE="REFERENCE">Wellisch 2002</LINK>). However, depression may often pass undiagnosed in patients with cancer (<LINK REF="REF-Greenberg-2004" TYPE="REFERENCE">Greenberg 2004</LINK>) and, even when identified, may be inadequately treated (<LINK REF="STD-Litofsky-2004" TYPE="STUDY">Litofsky 2004</LINK>; <LINK REF="REF-Sharpe-2004" TYPE="REFERENCE">Sharpe 2004</LINK>).</P>
<P>Antidepressants are recommended as a first-line treatment for moderate to severe depression in national guidelines (for example <LINK REF="REF-APA-2000" TYPE="REFERENCE">APA 2000</LINK>; <LINK REF="REF-NICE-2004" TYPE="REFERENCE">NICE 2004</LINK>). The three main pharmacological classes of antidepressant are the selective serotonin re-uptake inhibitors (SSRI), the tricyclic antidepressants (TCA) and the monoamine oxidase inhibitors (MAOI). A fourth class of newer, 'second-generation' compounds is chemically diverse. Other drug classes, for example psychostimulants (<LINK REF="REF-Weitzner-1999" TYPE="REFERENCE">Weitzner 1999</LINK>) or acetylcholinesterase inhibitors (<LINK REF="STD-Shaw-2006" TYPE="STUDY">Shaw 2006</LINK>) have also been proposed for use in patients with brain tumours. The many non-pharmacological treatments for depression (for example psychotherapy) are not covered in this review.</P>
<P>Although the precise mode of action is unknown (<LINK REF="REF-Moncrieff-2004" TYPE="REFERENCE">Moncrieff 2004</LINK>), meta-analyses of randomised controlled trials (RCTs) enrolling patients without brain tumours have shown antidepressants to be effective in the depressed elderly (<LINK REF="REF-Mottram-2006" TYPE="REFERENCE">Mottram 2006</LINK>) and in those with chronic low-level depression (<LINK REF="REF-Lima-2005" TYPE="REFERENCE">Lima 2005</LINK>), or severe or psychotic depression (<LINK REF="REF-Wijkstra-2005" TYPE="REFERENCE">Wijkstra 2005</LINK>). Antidepressants may reduce depressive symptoms in patients with other neurological illnesses (<LINK REF="REF-Hackett-2008" TYPE="REFERENCE">Hackett 2008</LINK>) but in the physically ill a limited response to treatment and high relapse rates are common observations (<LINK REF="REF-Iosifescu-2004" TYPE="REFERENCE">Iosifescu 2004</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Why it is important to do this study</HEADING>
<P>Major depressive disorder can affect up to 20% of brain tumour patients in the first eight months after diagnosis (<LINK REF="REF-Rooney-2011" TYPE="REFERENCE">Rooney 2011</LINK>) and can have important consequences for the affected person and their family. In glioma, depression has been associated with physical functional impairment (<LINK REF="REF-Rooney-2011" TYPE="REFERENCE">Rooney 2011</LINK>), cognitive impairment (<LINK REF="REF-Armstrong-2002" TYPE="REFERENCE">Armstrong 2002</LINK>), reduced quality of life (<LINK REF="REF-Mainio-2006" TYPE="REFERENCE">Mainio 2006</LINK>), higher mortality (<LINK REF="REF-Gathinji-2009" TYPE="REFERENCE">Gathinji 2009</LINK>; <LINK REF="STD-Litofsky-2004" TYPE="STUDY">Litofsky 2004</LINK>; <LINK REF="REF-Mainio-2006b" TYPE="REFERENCE">Mainio 2006b</LINK>), a greater frequency of medical complications (<LINK REF="STD-Litofsky-2004" TYPE="STUDY">Litofsky 2004</LINK>) and reduced work productivity (<LINK REF="REF-Feuerstein-2007" TYPE="REFERENCE">Feuerstein 2007</LINK>). Men with glioma may have the highest risk of all cancer patients of psychiatric hospitalisation in the year following glioma diagnosis (<LINK REF="REF-Dalton-2009" TYPE="REFERENCE">Dalton 2009</LINK>). Depression is a strong risk factor for suicide (<LINK REF="REF-Rihmer-2007" TYPE="REFERENCE">Rihmer 2007</LINK>) and epilepsy (<LINK REF="REF-Hesdorffer-2000" TYPE="REFERENCE">Hesdorffer 2000</LINK>) in patients without a brain tumour. If depression in brain tumour patients was effectively treated, personal or family suffering could potentially be reduced.</P>
<P>It is, however, possible that the side effects of antidepressants outweigh any benefit. Antidepressants may lower the seizure threshold (<LINK REF="REF-Montgomery-2005" TYPE="REFERENCE">Montgomery 2005</LINK>), impair memory (<LINK REF="REF-Peretti-2000" TYPE="REFERENCE">Peretti 2000</LINK>) or cause fatigue (<LINK REF="REF-Cassano-2004" TYPE="REFERENCE">Cassano 2004</LINK>) and patients with primary brain tumours are already at high risk of these complications. Despite clinical uncertainty, the effectiveness and potential adverse impact of pharmacotherapy for depression in primary brain tumours has not been systematically reviewed.</P>
</SUBSECTION>
</BACKGROUND>
<OBJECTIVES MODIFIED="2013-04-29 12:50:22 +0100" MODIFIED_BY="[Empty name]">
<P>To assess the benefits and harms of pharmacological treatment of depression in patients with a primary brain tumour. </P>
</OBJECTIVES>
<METHODS MODIFIED="2013-04-29 12:58:51 +0100" MODIFIED_BY="Gail Quinn">
<SELECTION_CRITERIA MODIFIED="2013-04-25 11:44:07 +0100" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2010-02-05 08:58:02 +0000" MODIFIED_BY="[Empty name]">
<P>For evidence of efficacy we aimed to include:</P>
<UL>
<LI>RCTs.</LI>
</UL>
<P>For evidence of adverse effects we also aimed to include:</P>
<UL>
<LI>non-randomised controlled studies;</LI>
<LI>cohort studies;</LI>
<LI>case-control studies.</LI>
</UL>
<P>We aimed to find all published and unpublished studies, in any language.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2013-04-25 11:44:07 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Inclusion criteria</HEADING>
<UL>
<LI>Adults (aged 18 years and over)</LI>
<LI>A diagnosis of depression at baseline (diagnosed by any validated method and satisfying the original trial authors that pharmacological treatment of depression was reasonable and necessary)</LI>
<LI>A co-morbid histological diagnosis of any primary brain tumour</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Exclusion criteria</HEADING>
<UL>
<LI>Studies recruiting only patients with metastatic (i.e. non-primary) brain tumours</LI>
</UL>
</SUBSECTION>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2010-02-05 09:01:51 +0000" MODIFIED_BY="[Empty name]">
<P>Any drug prescribed to treat depression compared, where relevant, with a control group receiving any other treatment. We anticipated that the most common drug class would be an antidepressant, but any category of prescription drug was eligible. Studies administering only unlicensed herbal remedies (for example St. John's wort) were excluded.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2013-04-25 11:44:07 +0100" MODIFIED_BY="[Empty name]">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2013-04-25 11:44:07 +0100" MODIFIED_BY="[Empty name]">
<P>The primary outcome was change in depression at final follow-up. We anticipated that this could be measured in several different ways:</P>
<UL>
<LI>the mean change in depression scale score;</LI>
<LI>the proportion of patients meeting pre-defined criteria for improvement in scale score;</LI>
<LI>changes in the proportion of patients with a categorical diagnosis of depression ('present' or 'absent').</LI>
</UL>
<P>Where both categorical (present or absent) and continuous (scale score) depression data were presented, we aimed to analyse both.</P>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2013-04-25 11:44:07 +0100" MODIFIED_BY="[Empty name]">
<P>These were:</P>
<UL>
<LI>quality of life;</LI>
<LI>general emotional distress;</LI>
<LI>length of time from diagnosis of brain tumour to death.</LI>
</UL>
<P>Although antidepressants can have many side effects, we identified those we considered most likely in brain tumour patients:</P>
<UL>
<LI>seizure frequency (measured by patient or carer report);</LI>
<LI>cognitive dysfunction (e.g. poor memory, measured by validated neuropsychological testing);</LI>
<LI>fatigue (measured by a validated rating scale).</LI>
</UL>
<P>We planned to analyse secondary outcomes as continuous variables only.</P>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2013-04-29 12:58:51 +0100" MODIFIED_BY="Gail Quinn">
<P>We ran searches for the original review in July 2009. We ran the subsequent (update) search in October 2012.</P>
<ELECTRONIC_SEARCHES MODIFIED="2013-04-29 12:58:51 +0100" MODIFIED_BY="Gail Quinn">
<P>We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (<I>The Cochrane Library </I>2012, Issue 10), MEDLINE (to October 2012), EMBASE (to October 2012) and PsycINFO (to October 2012). We had previously searched the British Nursing Index, LILACS, PSYNDEX, the NHS National Research Register, the NHS Centre for Reviews and Dissemination's Database of Abstracts of Reviews of Effectiveness (DARE) and Web of Knowledge (covering Science Scisearch, Social Sciences Citation Index and Biological Abstracts) (to July 2009). In the original review we constructed individual search strategies for each database (see <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK> to <LINK REF="APP-10" TYPE="APPENDIX">Appendix 10</LINK>). In the update, we amended search strategies where relevant to remove duplicate terms (<LINK REF="APP-11" TYPE="APPENDIX">Appendix 11</LINK> to <LINK REF="APP-14" TYPE="APPENDIX">Appendix 14</LINK>). Because we aimed to include studies other than RCTs, we conducted topic searches only.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2013-04-25 11:44:07 +0100" MODIFIED_BY="[Empty name]">
<P>We searched (July 2009):</P>
<UL>
<LI>Proquest Dissertations &amp; Theses;</LI>
<LI>System for Information on Grey Literature (SIGLE);</LI>
<LI>conference abstracts in the handsearched journals.</LI>
</UL>
<P>We contacted:</P>
<UL>
<LI>pharmaceutical companies manufacturing all antidepressants listed in the British National Formulary (BNF);</LI>
<LI>International Network of Agencies for HTA (INAHTA);</LI>
<LI>British Library Document Supply Centre (BLDSC).</LI>
</UL>
<P>We handsearched the following journals published in the years 1999 to 2009:</P>
<UL>
<LI>
<I>Journal of Neurology, Neurosurgery and Psychiatry</I>;</LI>
<LI>
<I>Journal of Neuro-oncology</I>;</LI>
<LI>
<I>Journal of Clinical Oncology</I>;</LI>
<LI>
<I>Neuro-oncology</I>.</LI>
</UL>
<P>We aimed to handsearch:</P>
<UL>
<LI>reference lists of eligible studies;</LI>
<LI>book chapters identified in the reference lists of eligible studies.</LI>
</UL>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2013-04-25 11:44:07 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<BR/>
</B>
</P>
<STUDY_SELECTION MODIFIED="2013-03-17 17:16:09 +0000" MODIFIED_BY="[Empty name]">
<P>Two authors (RG/AR) initially filtered studies from the title and abstract. We then obtained full copies of potentially relevant studies which two authors (RG/AR) independently assessed for eligibility. </P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2013-04-25 11:44:07 +0100" MODIFIED_BY="[Empty name]">
<P>Two review authors (RG, AR) were to extract data independently from eligible studies using a form. For the categorical outcome of depression we aimed to abstract the number of depressed patients in each arm at final follow-up in order to estimate risk ratio (RR). For continuous outcomes we aimed to abstract the mean and standard deviation (SD) of the outcome of interest in each arm at final follow-up.</P>
<P>We aimed to estimate from the means and SDs whether the data were skewed: if they were, we would write to authors requesting the mean and SDs of log transformed data.</P>
<P>For time-to-death data we aimed to abstract the hazard ratio (HR) and its variance from trial reports; if these were not presented, we would attempt either to estimate them or abstract relevant data from Kaplan-Meier survival curves. Failing this, we would estimate RR as outlined above.</P>
<P>Where possible, participants were to be analysed in the groups to which they were randomised, regardless of the treatment they actually received.</P>
<P>One review author (AR) was to enter data into RevMan 5 using the duplicate entry facility (<LINK REF="REF-RevMan-2012" TYPE="REFERENCE">RevMan 2012</LINK>).</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2013-04-25 11:44:07 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Randomisation</HEADING>
<P>We aimed to code the randomisation of participants to intervention groups as:<BR/>
</P>
<UL>
<LI>adequate e.g. a computer-generated random sequence or a table of random numbers;</LI>
<LI>quasi-randomised e.g. date of birth, clinic ID number or surname;</LI>
<LI>unclear e.g. not reported.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Allocation concealment</HEADING>
<P>We aimed to code allocation concealment from treatment providers and participants as:<BR/>
</P>
<UL>
<LI>adequate e.g. where the allocation sequence could not be foretold (A);</LI>
<LI>unclear e.g. not reported (B);</LI>
<LI>inadequate e.g. the computer-generated random sequence was displayed so treatment providers could see which arm of the trial the next participant was assigned to, or kept in a sealed opaque envelope (C);</LI>
<LI>not used (D).</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Blinding</HEADING>
<P>We aimed to code the blinding of participants, treatment providers and outcome assessors as:<BR/>
</P>
<UL>
<LI>yes;</LI>
<LI>no;</LI>
<LI>unclear.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Loss to follow-up</HEADING>
<P>We aimed to record the number of participants in each intervention arm whose outcomes were not reported at the end of the study, noting if loss to follow-up was not reported. Controlled non-randomised studies were to be similarly assessed, with analysis of whether:</P>
<UL>
<LI>the treatment and comparison groups were comparable at baseline;</LI>
<LI>analysis was adjusted for potential confounding factors.</LI>
</UL>
<P>If as a result of this assessment we considered it likely that a study was biased we were not to include it in the meta-analysis.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Statistical methods</HEADING>
<P>When summarising the categorical depression outcome we aimed to calculate risk ratios (RR). When comparing continuous outcome data from studies using different rating scales we aimed to use the standardised mean difference (SMD); for studies using the same scale we aimed to calculate the mean difference (MD).</P>
<P>For time-to-death data we aimed to pool HRs using the generic inverse variance facility of RevMan 5.</P>
<P>We aimed to use random-effects models for all meta-analyses.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Dealing with missing data</HEADING>
<P>Missing measures of uncertainty (for example confidence intervals and SDs) were to be calculated, where possible, or the study authors contacted to request their data. We did not intend to impute missing data.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Assessment of heterogeneity</HEADING>
<P>We aimed to calculate statistical heterogeneity using the I<SUP>2 </SUP>statistic, taking an I<SUP>2 </SUP>value of &gt; 50% as evidence of substantial heterogeneity (and a meta-analysis not being performed).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Funnel plot</HEADING>
<P>We aimed to examine funnel plots corresponding to the primary outcome. If treatment effects were thought not to be sampled from a symmetric distribution (an assumption of the random-effects model) we would use a fixed-effect model to conduct further meta-analyses.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Subgroup analysis</HEADING>
<P>We aimed to conduct subgroup analysis by antidepressant class, tumour histology and WHO grade of tumour.</P>
</SUBSECTION>
</QUALITY_ASSESSMENT>
<SENSITIVITY_ANALYSIS MODIFIED="2010-02-05 09:18:27 +0000" MODIFIED_BY="[Empty name]">
<P>We aimed to conduct sensitivity analyses by excluding studies which did not report adequate: (i) concealment of allocation or (ii) blinding of the outcome assessor.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2013-04-25 11:54:20 +0100" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2013-04-25 11:54:20 +0100" MODIFIED_BY="[Empty name]">
<P>We found no eligible studies for any of our primary or secondary outcomes.</P>
<P>Several studies, although interesting, were ineligible for this review. Wellisch et al conducted a RCT of a psychostimulant (methylphenidate) in patients with brain tumour, with depression as a secondary outcome (<LINK REF="STD-Wellisch-2006" TYPE="STUDY">Wellisch 2006</LINK>). However, it was not clear from the published conference abstract whether participation was limited to patients with depression and we were unable to contact the authors for clarification.</P>
<P>Morrow et al reported a RCT of an antidepressant (paroxetine) in a population of mixed cancer patients, including those with brain tumour. Although depression was measured as an outcome, the intervention was given primarily to treat fatigue and participation was not limited to depressed patients. Data for the small number of patients with brain tumours were not reported separately (<LINK REF="STD-Morrow-2003" TYPE="STUDY">Morrow 2003</LINK>).</P>
<P>Moss et al conducted an open-label phase II trial of an antidepressant (bupropion) on fatigue in mixed cancer patients, including those with brain tumour, and measured levels of depression. However, participation was restricted to patients with high levels of fatigue, not depression (<LINK REF="STD-Moss-2006" TYPE="STUDY">Moss 2006</LINK>).</P>
<P>Shaw et al enrolled 35 patients with mixed brain tumour pathologies to an open-label phase II trial of an acetylcholinesterase inhibitor (donepezil) and measured depression using a rating scale. However, participation was not limited to patients with depression (<LINK REF="STD-Shaw-2006" TYPE="STUDY">Shaw 2006</LINK>).</P>
<P>Meyers et al evaluated the effects of a psychostimulant (methylphenidate) in an open-label phase II trial of 30 patients with high-grade glioma, measuring depressive symptom severity among other outcomes. However, the authors explicitly excluded patients with major depression at study baseline (<LINK REF="STD-Meyers-1998" TYPE="STUDY">Meyers 1998</LINK>).</P>
<P>Litofsky et al conducted a prospective cohort study of adults with high-grade glioma, examining the relationship between depression and survival in glioma. However, the authors did not systematically prescribe treatment for depression and did not limit participation to patients with depression (<LINK REF="STD-Litofsky-2004" TYPE="STUDY">Litofsky 2004</LINK>).</P>
<P>Koval'chuk conducted a prospective cohort study of 225 patients following operation for brain tumour. The authors measured depression, among other outcomes, and assessed the influence of different antidepressants on the postoperative normalisation of mood. However, again, participation was not limited to depressed patients (<LINK REF="STD-Koval_x0027_chuk-2007" TYPE="STUDY">Koval'chuk 2007</LINK>).</P>
<P>Caudill et al conducted a retrospective cohort study of the frequency and toxicity of SSRI prescription among 160 glioblastoma patients presenting to a tertiary neuro-oncology service over a 10-year period. The authors reported that being prescribed SSRIs was associated with improved survival at two years post-diagnosis, after controlling for relevant confounders. Patients being prescribed a SSRI reported similar levels of toxicities as those on no SSRI. However, antidepressant prescription was uncontrolled and the study was not limited to depressed patients (<LINK REF="STD-Caudill-2011" TYPE="STUDY">Caudill 2011</LINK>).</P>
<P>Other studies that were ineligible on methodological grounds were a small uncontrolled case series (<LINK REF="STD-Rabey-1985" TYPE="STUDY">Rabey 1985</LINK>) and a single case study (<LINK REF="STD-Oyewumi-1981" TYPE="STUDY">Oyewumi 1981</LINK>).</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2009-09-07 10:32:47 +0100" MODIFIED_BY="[Empty name]">
<P>No eligible studies were found.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2009-09-07 10:33:05 +0100" MODIFIED_BY="[Empty name]">
<P>No eligible studies were found.</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2013-04-25 11:44:07 +0100" MODIFIED_BY="[Empty name]">
<P>We found no eligible randomised controlled trials (RCTs), controlled trials, cohort studies or case-control studies of the pharmacological treatment of depression in patients with primary brain tumours. Two RCTs, three phase II trials and three cohort studies examined aspects of drug treatment of symptoms in brain tumour patients. However, every trial recruited depressed and non-depressed patients alike, and every cohort study reported usual clinical care rather than systematically evaluating a specific treatment. The results do not therefore generalise easily to the question of treating depressed brain tumour patients that is the focus of this review. The lack of evidence is an important finding because depression is a common complication of brain tumour (<LINK REF="STD-Litofsky-2004" TYPE="STUDY">Litofsky 2004</LINK>; <LINK REF="REF-Wellisch-2002" TYPE="REFERENCE">Wellisch 2002</LINK>), with serious consequences for quality of life (<LINK REF="REF-Mainio-2006" TYPE="REFERENCE">Mainio 2006</LINK>) and possibly survival (<LINK REF="REF-Gathinji-2009" TYPE="REFERENCE">Gathinji 2009</LINK>; <LINK REF="STD-Litofsky-2004" TYPE="STUDY">Litofsky 2004</LINK>; <LINK REF="REF-Mainio-2006b" TYPE="REFERENCE">Mainio 2006b</LINK>). Doctors need to know how to treat it.</P>
<P>Although national guidelines for the treatment of depression exist (for example <LINK REF="REF-APA-2000" TYPE="REFERENCE">APA 2000</LINK>; <LINK REF="REF-NICE-2004" TYPE="REFERENCE">NICE 2004</LINK>), they cannot have been based on evidence specific to brain tumours because we failed to find any studies that were eligible for this review. Antidepressants appear to be effective in patients with other medical illnesses, but their effectiveness in patients with a brain tumour should not be assumed. Brain tumours are rapidly progressive, biologically active and with significant structural and functional effects upon the main organ implicated in depression. Brain tumours (and their surgical treatment) may disrupt neuronal circuits crucial to the experience of emotion (<LINK REF="REF-Litofsky-2009" TYPE="REFERENCE">Litofsky 2009</LINK>) or else alter local levels of biochemical mediators (<LINK REF="REF-Mainio-2005" TYPE="REFERENCE">Mainio 2005</LINK>). Antiepileptic drugs can affect the bioavailability of antidepressants (<LINK REF="REF-Hachad-2002" TYPE="REFERENCE">Hachad 2002</LINK>) and corticosteroids have been associated with mood changes in glioma (<LINK REF="STD-Litofsky-2004" TYPE="STUDY">Litofsky 2004</LINK>). There are many reasons to be cautious about assuming that antidepressants are effective in brain tumour patients.</P>
<P>Brain cancer is also associated with epilepsy, cognitive dysfunction and fatigue (<LINK REF="REF-Pace-1998" TYPE="REFERENCE">Pace 1998</LINK>; <LINK REF="REF-Wen-2008" TYPE="REFERENCE">Wen 2008</LINK>), which are recognised side effects of antidepressants (<LINK REF="REF-Cassano-2004" TYPE="REFERENCE">Cassano 2004</LINK>; <LINK REF="REF-Montgomery-2005" TYPE="REFERENCE">Montgomery 2005</LINK>; <LINK REF="REF-Peretti-2000" TYPE="REFERENCE">Peretti 2000</LINK>). It is important to highlight the lack of evidence about the possible adverse effects of antidepressants in these high-risk patients. Antidepressants could also improve these outcomes, since depression has itself been associated with epilepsy (<LINK REF="REF-Hesdorffer-2000" TYPE="REFERENCE">Hesdorffer 2000</LINK>), impaired cognition (<LINK REF="REF-Stefanova-2006" TYPE="REFERENCE">Stefanova 2006</LINK>) and fatigue (<LINK REF="STD-Moss-2006" TYPE="STUDY">Moss 2006</LINK>).</P>
<P>Three excluded studies used a pharmacological agent other than an antidepressant (a psychostimulant or an acetylcholinesterase inhibitor). These drugs could help treat a wider range of symptoms than antidepressants. To date, however, no studies have primarily evaluated the benefit, or harm, of pharmacological treatment of depression in patients with a primary brain tumour. Direct study of this question requires that eligibility is restricted to patients with high levels of depression at baseline.</P>
<SUBSECTION>
<HEADING LEVEL="2">Potential biases in the overview process</HEADING>
<P>Our search strategy was not designed to identify qualitative research studies, describing the individual's experience of having a brain tumour. Results from RCTs and other quantitative study designs provide information about the 'average' response to treatment but may not easily be applied to individual patients. Although the search strategy was thorough for antidepressants, we may have missed studies of other pharmacological agents. Searches on the foreign language databases (LILACS and PSYNDEX) were limited mainly to English language terms. English translations of abstracts are often included in these databases so it is possible, but unlikely, that we missed important relevant studies. We assumed that the lack of response from any drug companies is indeed because they have not studied this issue.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Agreement or disagreement with other reviews</HEADING>
<P>Authors of other reviews of depression in brain tumours (<LINK REF="REF-Litofsky-2009" TYPE="REFERENCE">Litofsky 2009</LINK>; <LINK REF="REF-Pangilinan-2007" TYPE="REFERENCE">Pangilinan 2007</LINK>; <LINK REF="REF-Price-2008" TYPE="REFERENCE">Price 2008</LINK>; <LINK REF="REF-Weitzner-1999" TYPE="REFERENCE">Weitzner 1999</LINK>) note a similar lack of evidence.</P>
</SUBSECTION>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2013-04-25 11:44:07 +0100" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2013-04-25 11:44:07 +0100" MODIFIED_BY="[Empty name]">
<P>Since the last version of this review none of the new relevant studies have provided additional information to change the conclusions. There is currently no high-quality evidence as to whether pharmacological treatments for depression in patients with primary brain tumours are effective, or harmful. Best practice would suggest that doctors treating depressed brain tumour patients discuss the lack of evidence with the patient, document their views and use their clinical judgement. If drug treatment is started, close follow-up may help detect any adverse effects.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2013-04-25 11:44:07 +0100" MODIFIED_BY="[Empty name]">
<P>Detailed prospective studies and randomised controlled trials addressing the risks and benefits of antidepressants are vital. Important research questions include whether, among patients with a primary brain tumour and depression, there is any evidence that treatment:</P>
<UL>
<LI>is effective in treating depression;</LI>
<LI>has clinically significant effects on seizure frequency, fatigue and cognition;</LI>
<LI>has clinically significant pharmacokinetic interactions with antiepileptic drugs or chemotherapy;</LI>
<LI>has a clinically significant effect on survival.</LI>
</UL>
<P>When next updating this review we will widen our search terms to include psychostimulants and acetylcholinesterase inhibitors.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2013-04-25 11:44:07 +0100" MODIFIED_BY="[Empty name]">
<P>We thank Heather Dickinson, Steff Lewis, Dr NS Litofsky, Dr E Davies, Sandi Pniauskas and Lesley Smith for their helpful comments on previous versions of this review. We thank Jane Hayes for help updating and running search strategies for the current version of this review.</P>
<P>The National Institute for Health Research (NIHR) is the largest single funder of the Cochrane Gynaecological Cancer Group. </P>
<P>The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the NIHR, NHS or the Department of Health.<BR/>
</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2009-09-07 11:09:36 +0100" MODIFIED_BY="[Empty name]">
<P>AR developed and wrote the review, supervised by RG.<BR/>
</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2010-02-05 09:37:13 +0000" MODIFIED_BY="[Empty name]">
<P>The title was changed to specify that the review was of interventions for the treatment of depression (as opposed to prevention).</P>
<P>The British Nursing Index was searched in place of CINAHL, since CINAHL was not available on Ovid. CancerLit was not searched because it is covered by MEDLINE. Applied Science and Technology Plus was not searched as it is an engineering database. General Science Plus could not be accessed from Edinburgh University. The search strategy outlined in the protocol was altered, as necessary, for individual databases; for full details see the Appendices.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2016-09-21 14:29:23 +0100" MODIFIED_BY="Tracey Harrison">
<STUDIES MODIFIED="2013-04-25 12:00:24 +0100" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2013-04-07 12:27:09 +0100" MODIFIED_BY="[Empty name]"/>
<EXCLUDED_STUDIES MODIFIED="2013-04-25 12:00:24 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Caudill-2011" MODIFIED="2013-04-25 11:44:07 +0100" MODIFIED_BY="[Empty name]" NAME="Caudill 2011" YEAR="2011">
<REFERENCE MODIFIED="2013-04-25 11:44:07 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Caudill JS, Brown PD, Cerhan JH, Rummans TA</AU>
<TI>Selective serotonin reuptake inhibitors, glioblastoma multiforme, and impact on toxicities and overall survival. The Mayo Clinic experience</TI>
<SO>American Journal of Clinical Oncology</SO>
<YR>2011</YR>
<VL>34</VL>
<PG>385-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2615930"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2615929"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Koval_x0027_chuk-2007" MODIFIED="2010-01-21 14:18:09 +0000" MODIFIED_BY="[Empty name]" NAME="Koval'chuk 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-01-21 14:18:09 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Koval'chuk VV</AU>
<TI>Pharmacologic correction of psycho-emotive disorders in the rehabilitation of patients after removal of brain tumors</TI>
<TO>Original title unavailable (Russian)</TO>
<SO>Voprosy Onkologii</SO>
<YR>2007</YR>
<VL>53</VL>
<NO>6</NO>
<PG>704-10</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2615932"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2615931"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Litofsky-2004" MODIFIED="2009-09-08 21:23:59 +0100" MODIFIED_BY="[Empty name]" NAME="Litofsky 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-09-08 21:23:59 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Litofsky NS, Farace E, Anderson F Jr</AU>
<TI>Depression in patients with high-grade glioma: results of the Glioma Outcomes Project</TI>
<SO>Neurosurgery</SO>
<YR>2004</YR>
<VL>54</VL>
<NO>2</NO>
<PG>358-66</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2615934"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2615933"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Meyers-1998" MODIFIED="2009-09-08 21:23:10 +0100" MODIFIED_BY="[Empty name]" NAME="Meyers 1998" YEAR="1998">
<REFERENCE MODIFIED="2009-09-08 21:23:10 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Meyers CA, Weitzner MA, Valentine AD, Levin VA</AU>
<TI>Methylphenidate therapy improves cognition, mood, and function of brain tumor patients</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>1998</YR>
<VL>16</VL>
<NO>7</NO>
<PG>2522-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2615936"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2615935"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Morrow-2003" MODIFIED="2009-09-08 21:32:44 +0100" MODIFIED_BY="[Empty name]" NAME="Morrow 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-09-08 21:32:44 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Morrow GR, Hickok JT, Roscoe JA, Raubertas RF, Andrews PLR, Flynn PJ</AU>
<TI>Differential effects of paroxetine on fatigue and depression: a randomized, double-blind trial from the University of Rochester Cancer Centre Community Clinical Oncology Programme</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2003</YR>
<VL>21</VL>
<NO>24</NO>
<PG>4635-41</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2615938"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2615937"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Moss-2006" MODIFIED="2010-02-05 09:40:22 +0000" MODIFIED_BY="[Empty name]" NAME="Moss 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-02-05 09:40:22 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Moss EL, Simpson JSA, Pelletier G, Forsyth P</AU>
<TI>An open-label study of the effects of bupropion SR on fatigue, depression and quality of life of mixed-site cancer patients and their partners</TI>
<SO>Psycho-oncology</SO>
<YR>2006</YR>
<VL>15</VL>
<PG>259-67</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2615940"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2615939"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Oyewumi-1981" MODIFIED="2009-09-08 20:35:18 +0100" MODIFIED_BY="[Empty name]" NAME="Oyewumi 1981" YEAR="1981">
<REFERENCE MODIFIED="2009-09-08 20:35:15 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Oyewumi LK, Lapierre YD</AU>
<TI>Efficacy of lithium in treating mood disorder occurring after brain stem injury</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1981</YR>
<VL>138</VL>
<NO>1</NO>
<PG>110-2</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2615942"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2615941"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rabey-1985" MODIFIED="2009-09-08 21:27:52 +0100" MODIFIED_BY="[Empty name]" NAME="Rabey 1985" YEAR="1985">
<REFERENCE MODIFIED="2009-09-08 21:27:52 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rabey JM, Avrahami E</AU>
<TI>Unmasking of cerebellar tumours by amitriptyline in depressive patients</TI>
<SO>Journal of Neurology, Neurosurgery and Psychiatry</SO>
<YR>1985</YR>
<VL>48</VL>
<NO>3</NO>
<PG>291</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2615944"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2615943"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shaw-2006" MODIFIED="2013-04-25 12:00:24 +0100" MODIFIED_BY="[Empty name]" NAME="Shaw 2006" YEAR="2006">
<REFERENCE MODIFIED="2013-04-25 12:00:24 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shaw EG, Rosdhal R, D'Agostino Jr RB, Lovato J, Naughton MJ, Robbins ME et al</AU>
<TI>Phase II study of donepezil in irradiated brain tumor patients: Effect on cognitive function, mood, and quality of life</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2006</YR>
<VL>24</VL>
<NO>9</NO>
<PG>1415-20</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2615946"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2615945"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wellisch-2006" MODIFIED="2010-02-05 09:42:30 +0000" MODIFIED_BY="[Empty name]" NAME="Wellisch 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-02-05 09:42:30 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wellisch DK, Steh B, Kaleita TA, Graham CA, Cloughes TF</AU>
<TI>A modafinil therapeutic trial for adult brain tumor patients: III. Depression outcomes</TI>
<SO>Psycho-oncology</SO>
<YR>2006</YR>
<VL>15 Suppl</VL>
<PG>455</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2615948"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2615947"/></IDENTIFIERS>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2010-01-21 14:18:09 +0000" MODIFIED_BY="[Empty name]"/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2013-04-25 11:44:07 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2013-04-25 11:44:07 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-APA-2000" MODIFIED="2013-04-25 11:06:30 +0100" MODIFIED_BY="[Empty name]" NAME="APA 2000" TYPE="JOURNAL_ARTICLE">
<AU>American Psychiatric Association</AU>
<TI>Practice guideline for the treatment of patients with major depressive disorder (revision)</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2000</YR>
<VL>157 Suppl 4</VL>
<PG>1-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-APA-2000b" MODIFIED="2013-04-25 11:44:07 +0100" MODIFIED_BY="[Empty name]" NAME="APA 2000b" TYPE="BOOK">
<AU>American Psychiatric Association</AU>
<TI>Diagnostic and Statistical Manual of Mental Disorders (4th edition, text rev.)</TI>
<SO>Diagnostic and Statistical Manual of Mental Disorders (4th edition, text revision)</SO>
<YR>2000</YR>
<PB>American Psychiatric Association</PB>
<CY>Washington DC</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Armstrong-2002" MODIFIED="2010-01-05 12:00:55 +0000" MODIFIED_BY="[Empty name]" NAME="Armstrong 2002" TYPE="JOURNAL_ARTICLE">
<AU>Armstrong CL, Goldstein B, Cohen B et al</AU>
<TI>Clinical predictors of depression in patients with low-grade brain tumors: consideration of a neurologic versus a psychogenic model</TI>
<SO>Journal of Clinical Psychology in Medical Settings</SO>
<YR>2002</YR>
<VL>9</VL>
<NO>2</NO>
<PG>97-107</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Barnholtz_x002d_Sloan-2003" NAME="Barnholtz-Sloan 2003" TYPE="JOURNAL_ARTICLE">
<AU>Barnholtz-Sloan JS, Sloan AE, Schwartz AG</AU>
<TI>Relative survival rates and patterns of diagnosis analyzed by time period for individuals with primary malignant brain tumour, 1973-1997</TI>
<SO>Journal of Neurosurgery</SO>
<YR>2003</YR>
<VL>99</VL>
<NO>3</NO>
<PG>458-66</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cassano-2004" NAME="Cassano 2004" TYPE="JOURNAL_ARTICLE">
<AU>Cassano P, Fava M</AU>
<TI>Tolerability issues during long-term treatment with antidepressants</TI>
<SO>Annals of Clinical Psychiatry</SO>
<YR>2004</YR>
<VL>16</VL>
<NO>1</NO>
<PG>15-25</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dalton-2009" MODIFIED="2010-01-21 17:01:52 +0000" MODIFIED_BY="[Empty name]" NAME="Dalton 2009" TYPE="JOURNAL_ARTICLE">
<AU>Dalton SO, Laursen TM, Ross L, Mortensen PB, Johansen C</AU>
<TI>Risk for hospitalisation with depression after a cancer diagnosis: a nationwide, population-based study of cancer patients in Denmark from 1973 to 2003</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2009</YR>
<VL>27</VL>
<PG>1440-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Feuerstein-2007" MODIFIED="2013-04-25 11:44:07 +0100" MODIFIED_BY="[Empty name]" NAME="Feuerstein 2007" TYPE="JOURNAL_ARTICLE">
<AU>Feuerstein M, Hansen JA, Calvio LC, Johnson L, Ronquillo JG</AU>
<TI>Work productivity in brain tumor survivors</TI>
<SO>Journal of Occupational and Environmental Medicine</SO>
<YR>2007</YR>
<VL>49</VL>
<PG>803-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-First-2002" MODIFIED="2009-09-22 14:13:24 +0100" MODIFIED_BY="Gail Quinn" NAME="First 2002" TYPE="OTHER">
<AU>First MB, Spitzer RL, Gibbon M</AU>
<TI>Structured Clinical Interview for DSM-IV-TR Axis I disorders</TI>
<SO>Patient Edition (SCID-I/P, 11/2002 revision)</SO>
<YR>2002</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gathinji-2009" MODIFIED="2010-01-05 11:55:28 +0000" MODIFIED_BY="[Empty name]" NAME="Gathinji 2009" TYPE="JOURNAL_ARTICLE">
<AU>Gathinji M, McGirt M, Attenello F, Chaichana K, Than K, Olivi A et al</AU>
<TI>Association of preoperative depression and survival after resection of malignant brain astrocytoma</TI>
<SO>Surgical Neurology</SO>
<YR>2009</YR>
<VL>71</VL>
<NO>3</NO>
<PG>299-303</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gelder-2000" MODIFIED="2010-02-05 09:45:35 +0000" MODIFIED_BY="[Empty name]" NAME="Gelder 2000" TYPE="BOOK">
<AU>Gelder M (editor)</AU>
<SO>Oxford Textbook of Psychiatry</SO>
<YR>2000</YR>
<PB>Oxford University Press</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Greenberg-2004" NAME="Greenberg 2004" TYPE="JOURNAL_ARTICLE">
<AU>Greenberg DB</AU>
<TI>Barriers to the treatment of depression in cancer patients</TI>
<SO>Journal of the National Cancer Institute. Monographs</SO>
<YR>2004</YR>
<VL>32</VL>
<PG>127-35</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hachad-2002" MODIFIED="2009-09-08 20:30:56 +0100" MODIFIED_BY="[Empty name]" NAME="Hachad 2002" TYPE="JOURNAL_ARTICLE">
<AU>Hachad H, Ragueneau-Majlessi I, Levy RH</AU>
<TI>New antiepileptic drugs: review on drug interactions</TI>
<SO>Therapeutic Drug Monitoring</SO>
<YR>2002</YR>
<VL>24</VL>
<NO>1</NO>
<PG>91-103</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hackett-2008" MODIFIED="2013-04-25 11:44:07 +0100" MODIFIED_BY="Gail Quinn" NAME="Hackett 2008" TYPE="COCHRANE_REVIEW">
<AU>Hackett ML, Anderson CS, House AO, Xia J</AU>
<TI>Interventions for treating depression after stroke</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2008</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2013-04-25 11:10:57 +0100" MODIFIED_BY="Gail Quinn"><IDENTIFIER MODIFIED="2013-04-25 11:10:57 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD003437.pub3"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Hesdorffer-2000" MODIFIED="2009-09-10 13:30:10 +0100" MODIFIED_BY="[Empty name]" NAME="Hesdorffer 2000" TYPE="JOURNAL_ARTICLE">
<AU>Hesdorffer DC, Hauser WA, Annegers JF, Cascino G</AU>
<TI>Major depression is a risk factor for seizures in older adults</TI>
<SO>Annals of Neurology</SO>
<YR>2000</YR>
<VL>47</VL>
<PG>246-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Iosifescu-2004" NAME="Iosifescu 2004" TYPE="JOURNAL_ARTICLE">
<AU>Iosifescu DV, Bankier B, Fava M</AU>
<TI>Impact of medical co-morbid disease on antidepressant treatment of major depressive disorder</TI>
<SO>Current Psychiatry Reports</SO>
<YR>2004</YR>
<VL>6</VL>
<NO>3</NO>
<PG>193-201</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lima-2005" MODIFIED="2013-04-25 11:44:07 +0100" MODIFIED_BY="Gail Quinn" NAME="Lima 2005" TYPE="COCHRANE_REVIEW">
<AU>Lima MS, Moncrieff J, Soares BGO</AU>
<TI>Drugs versus placebo for dysthymia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2005</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2013-04-25 11:12:49 +0100" MODIFIED_BY="Gail Quinn"><IDENTIFIER MODIFIED="2013-04-25 11:12:49 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001130"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Litofsky-2009" MODIFIED="2013-04-25 11:44:07 +0100" MODIFIED_BY="[Empty name]" NAME="Litofsky 2009" TYPE="OTHER">
<AU>Litofsky NS, Resnick AG</AU>
<TI>The relationship between depression and brain tumours</TI>
<SO>Journal of Neuro-oncology</SO>
<YR>2009 Mar 5 [Epub ahead of print]</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Louis-2007" MODIFIED="2013-04-25 11:44:07 +0100" MODIFIED_BY="Gail Quinn" NAME="Louis 2007" TYPE="JOURNAL_ARTICLE">
<AU>Louis DN, Ohgaki H, Wiestler OD</AU>
<TI>The 2007 classification of tumours of the central nervous system</TI>
<SO>Acta Neuropathologica</SO>
<YR>2007</YR>
<VL>114</VL>
<NO>2</NO>
<PG>97-109</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mainio-2005" MODIFIED="2013-04-25 11:44:07 +0100" MODIFIED_BY="[Empty name]" NAME="Mainio 2005" TYPE="JOURNAL_ARTICLE">
<AU>Mainio A, Hakko H, Timonen M, Niemelä A, Koivukangas J, Räsänen P</AU>
<TI>Depression in relation to survival among neurosurgical patients with a primary brain tumor: a 5-year follow-up study</TI>
<SO>Neurosurgery</SO>
<YR>2005</YR>
<VL>56</VL>
<PG>1234-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mainio-2006" MODIFIED="2010-02-05 09:51:20 +0000" MODIFIED_BY="[Empty name]" NAME="Mainio 2006" TYPE="JOURNAL_ARTICLE">
<AU>Mainio A, Hakko H, Niemela A</AU>
<TI>Gender difference in relation to depression and quality of life among patients with a primary brain tumour</TI>
<SO>European Psychiatry: the journal of the Association of European Psychiatrists</SO>
<YR>2006</YR>
<VL>21</VL>
<NO>3</NO>
<PG>194-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mainio-2006b" NAME="Mainio 2006b" TYPE="JOURNAL_ARTICLE">
<AU>Mainio A, Tuunanen S, Hakko H</AU>
<TI>Decreased quality of life and depression as predictors for shorter survival among patients with low-grade gliomas: a follow-up from 1990 to 2003</TI>
<SO>European Archives of Psychiatry and Clinical Neuroscience</SO>
<YR>2006</YR>
<VL>256</VL>
<NO>8</NO>
<PG>516-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moncrieff-2004" MODIFIED="2013-04-25 11:44:07 +0100" MODIFIED_BY="Gail Quinn" NAME="Moncrieff 2004" TYPE="COCHRANE_REVIEW">
<AU>Moncrieff J, Wessely S, Hardy R</AU>
<TI>Active placebos versus antidepressants for depression</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2004</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2013-04-25 11:15:58 +0100" MODIFIED_BY="Gail Quinn"><IDENTIFIER MODIFIED="2013-04-25 11:15:58 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD003012.pub2"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Montgomery-2005" NAME="Montgomery 2005" TYPE="JOURNAL_ARTICLE">
<AU>Montgomery SA</AU>
<TI>Antidepressants and seizures: emphasis on newer agents and clinical implications</TI>
<SO>International Journal of Clinical Practice</SO>
<YR>2005</YR>
<VL>59</VL>
<NO>12</NO>
<PG>1435-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mottram-2006" MODIFIED="2013-04-25 11:44:07 +0100" MODIFIED_BY="Gail Quinn" NAME="Mottram 2006" TYPE="COCHRANE_REVIEW">
<AU>Mottram P, Wilson K, Strobl J</AU>
<TI>Antidepressants for depressed elderly</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2006</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2013-04-25 11:16:51 +0100" MODIFIED_BY="Gail Quinn"><IDENTIFIER MODIFIED="2013-04-25 11:16:51 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD003491.pub2"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-NICE-2004" MODIFIED="2013-04-25 11:44:07 +0100" MODIFIED_BY="[Empty name]" NAME="NICE 2004" TYPE="OTHER">
<TI>Management of depression in primary and secondary care. National Clinical Practice Guideline No. 23</TI>
<SO>London: National Institute for Health and Care Excellence</SO>
<YR>2004</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pace-1998" NAME="Pace 1998" TYPE="JOURNAL_ARTICLE">
<AU>Pace A, Bove L, Innocenti P</AU>
<TI>Epilepsy and gliomas: incidence and treatment in 119 patients</TI>
<SO>Journal of Experimental and Clinical Cancer Research</SO>
<YR>1998</YR>
<VL>17</VL>
<NO>4</NO>
<PG>479-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pangilinan-2007" MODIFIED="2009-09-08 20:25:50 +0100" MODIFIED_BY="[Empty name]" NAME="Pangilinan 2007" TYPE="JOURNAL_ARTICLE">
<AU>Pangilinan PH Jr., Kelly BM, Pangilinan JM</AU>
<TI>Depression in the patient with brain cancer</TI>
<SO>Community Oncology</SO>
<YR>2007</YR>
<VL>4</VL>
<PG>533-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Parkin-2005" NAME="Parkin 2005" TYPE="OTHER">
<AU>Parkin DM, Whelan SL, Ferlay J</AU>
<TI>Cancer incidence in five continents, vol. I to VIII</TI>
<SO>IARC Cancerbase No 7, Lyon</SO>
<YR>2005</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Peretti-2000" MODIFIED="2010-02-05 09:52:21 +0000" MODIFIED_BY="[Empty name]" NAME="Peretti 2000" TYPE="JOURNAL_ARTICLE">
<AU>Peretti S, Judge R, Hindmarch I</AU>
<TI>Safety and tolerability considerations: tricyclic antidepressants vs. selective serotonin re-uptake inhibitors (Antidepressant selection: Proceedings from a TCA/SSRI consensus conference)</TI>
<SO>Acta Psychiatrica Scandinavia</SO>
<YR>2000</YR>
<VL>101 Suppl 403</VL>
<PG>17-25</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pignatti-2002" NAME="Pignatti 2002" TYPE="JOURNAL_ARTICLE">
<AU>Pignatti F, van den Bent M, Curran D</AU>
<TI>Prognostic factors for survival in adult patients with cerebral low-grade glioma</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2002</YR>
<VL>20</VL>
<NO>8</NO>
<PG>2076-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Price-2008" MODIFIED="2010-01-21 16:39:46 +0000" MODIFIED_BY="[Empty name]" NAME="Price 2008" TYPE="BOOK_SECTION">
<AU>Price TRP, Goetz KL, Lovell MR</AU>
<TI>Neuropsychiatric aspects of brain tumors</TI>
<SO>The American Psychiatric Publishing Textbook of Neuropsychiatry and Behavioural Neurosciences</SO>
<YR>2008</YR>
<EN>5th</EN>
<ED>Yudofsky SC, Hales RE</ED>
<PB>American Psychiatric Publishing Inc.</PB>
<CY>Arlington</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2012" MODIFIED="2013-04-25 11:44:07 +0100" MODIFIED_BY="[Empty name]" NAME="RevMan 2012" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2012</YR>
<EN>5.2</EN>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rihmer-2007" NAME="Rihmer 2007" TYPE="JOURNAL_ARTICLE">
<AU>Rihmer Z</AU>
<TI>Suicide risk in mood disorders</TI>
<SO>Current Opinion in Psychiatry</SO>
<YR>2007</YR>
<VL>20</VL>
<PG>17-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rooney-2011" MODIFIED="2013-04-25 11:44:07 +0100" MODIFIED_BY="[Empty name]" NAME="Rooney 2011" TYPE="JOURNAL_ARTICLE">
<AU>Rooney AG, McNamara S, MacKinnon M, Fraser M, Rampling R, Carson A et al</AU>
<TI>Frequency, clinical associations, and longitudinal course of major depressive disorder in adults with cerebral glioma</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2011</YR>
<VL>29</VL>
<PG>4307-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sharpe-2004" MODIFIED="2010-02-05 09:52:55 +0000" MODIFIED_BY="[Empty name]" NAME="Sharpe 2004" TYPE="JOURNAL_ARTICLE">
<AU>Sharpe M, Strong V, Allen K</AU>
<TI>Major depression in outpatients attending a regional cancer centre: screening and unmet treatment needs</TI>
<SO>British Journal of Cancer</SO>
<YR>2004</YR>
<VL>90</VL>
<PG>314-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stefanova-2006" NAME="Stefanova 2006" TYPE="JOURNAL_ARTICLE">
<AU>Stefanova E, Potrebic A, Ziropdja L</AU>
<TI>Depression predicts the pattern of cognitive impairment in early Parkinson's disease</TI>
<SO>Journal of the Neurological Sciences</SO>
<YR>2006</YR>
<VL>248</VL>
<PG>131-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Strong-2007" MODIFIED="2013-04-25 11:44:07 +0100" MODIFIED_BY="[Empty name]" NAME="Strong 2007" TYPE="JOURNAL_ARTICLE">
<AU>Strong V, Waters R, Hibberd C, Rush R, Cargill A, Storey D et al</AU>
<TI>Emotional distress in cancer patients: the Edinburgh Cancer Centre symptoms study</TI>
<SO>British Journal of Cancer</SO>
<YR>2007</YR>
<VL>96</VL>
<NO>6</NO>
<PG>868-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stupp-2005" MODIFIED="2010-01-21 17:03:42 +0000" MODIFIED_BY="[Empty name]" NAME="Stupp 2005" TYPE="JOURNAL_ARTICLE">
<AU>Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB et al</AU>
<TI>Radiotherapy plus concomitant and adjuvant chemotherapy for glioblastoma</TI>
<SO>New England Journal of Medicine</SO>
<YR>2005</YR>
<VL>352</VL>
<PG>987-96</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Van-den-Bent-2005" NAME="Van den Bent 2005" TYPE="JOURNAL_ARTICLE">
<AU>Van Den Bent MJ, Afra D, de Witte O</AU>
<TI>Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial</TI>
<SO>Lancet</SO>
<YR>2005</YR>
<VL>366</VL>
<PG>985-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Weitzner-1999" MODIFIED="2010-01-05 14:36:33 +0000" MODIFIED_BY="[Empty name]" NAME="Weitzner 1999" TYPE="JOURNAL_ARTICLE">
<AU>Weitzner MA</AU>
<TI>Psychosocial and neuropsychiatric aspects of patients with primary brain tumors</TI>
<SO>Cancer Investigation</SO>
<YR>1999</YR>
<VL>17</VL>
<NO>4</NO>
<PG>285-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wellisch-2002" NAME="Wellisch 2002" TYPE="JOURNAL_ARTICLE">
<AU>Wellisch DK, Kaleita TA, Freeman D</AU>
<TI>Predicting major depression in brain tumour patients</TI>
<SO>Psycho-oncology</SO>
<YR>2002</YR>
<VL>11</VL>
<PG>230-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wen-2008" MODIFIED="2009-09-10 15:44:01 +0100" MODIFIED_BY="[Empty name]" NAME="Wen 2008" TYPE="JOURNAL_ARTICLE">
<AU>Wen PY, Kesari S</AU>
<TI>Malignant gliomas in adults</TI>
<SO>New England Journal of Medicine</SO>
<YR>2008</YR>
<VL>359</VL>
<PG>492-507</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wijkstra-2005" MODIFIED="2013-04-25 11:44:07 +0100" MODIFIED_BY="Gail Quinn" NAME="Wijkstra 2005" TYPE="COCHRANE_REVIEW">
<AU>Wijkstra J, Lijmer J, Balk F, Geddes J, Nolen WA</AU>
<TI>Pharmacological treatment for psychotic depression</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2005</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2013-04-25 11:38:49 +0100" MODIFIED_BY="Gail Quinn"><IDENTIFIER MODIFIED="2013-04-25 11:38:49 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD004044.pub2"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Wrensch-2002" NAME="Wrensch 2002" TYPE="JOURNAL_ARTICLE">
<AU>Wrensch M, Minn Y, Chew T</AU>
<TI>Epidemiology of primary brain tumours: current concepts and review of the literature</TI>
<SO>Neuro-oncology</SO>
<YR>2002</YR>
<VL>4</VL>
<PG>278-99</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Zigmond-1968" NAME="Zigmond 1968" TYPE="JOURNAL_ARTICLE">
<AU>Zigmond AS, Snaith RP</AU>
<TI>The Hospital Anxiety and Depression Scale</TI>
<SO>Acta Psychiatrica Scandinavia</SO>
<YR>1968</YR>
<VL>67</VL>
<PG>361-70</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2013-04-25 11:40:14 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Rooney-2010" MODIFIED="2013-04-25 11:40:14 +0100" MODIFIED_BY="[Empty name]" NAME="Rooney 2010" TYPE="COCHRANE_REVIEW">
<AU>Rooney A, Grant R</AU>
<TI>Pharmacological treatment of depression in patients with a primary brain tumour</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2010</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2013-04-25 11:40:14 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2013-04-25 11:40:14 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD006932.pub2"/></IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2013-04-25 11:44:07 +0100" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2013-04-07 12:27:09 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2013-04-25 11:44:07 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2013-04-25 11:44:07 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Caudill-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-04-25 11:44:07 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment of depression was based on routine clinical care (not systematically controlled)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-04-25 11:44:07 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Koval_x0027_chuk-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-04-25 11:44:07 +0100" MODIFIED_BY="[Empty name]">
<P>Depression was not a necessary inclusion criterion</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-04-25 11:44:07 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Litofsky-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-04-25 11:44:07 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment of depression was not systematically controlled<BR/>Depression was not a necessary inclusion criterion</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-04-25 11:44:07 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Meyers-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-04-25 11:44:07 +0100" MODIFIED_BY="[Empty name]">
<P>Patients with severe depression were excluded and the study was not limited to those with milder depression</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-04-25 11:44:07 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Morrow-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-04-25 11:44:07 +0100" MODIFIED_BY="[Empty name]">
<P>Depression was not a necessary study inclusion criterion<BR/>Data for brain tumour patients were not presented separately</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-04-25 11:44:07 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Moss-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-04-25 11:44:07 +0100" MODIFIED_BY="[Empty name]">
<P>Depression was not a necessary study inclusion criterion<BR/>Data for brain tumour patients were not presented separately</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-04-25 11:44:07 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Oyewumi-1981">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-04-25 11:44:07 +0100" MODIFIED_BY="[Empty name]">
<P>Single case study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-04-25 11:44:07 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rabey-1985">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-04-25 11:44:07 +0100" MODIFIED_BY="[Empty name]">
<P>3 case studies; brain tumour not diagnosed at time of antidepressant prescription</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-04-25 11:44:07 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Shaw-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-04-25 11:44:07 +0100" MODIFIED_BY="[Empty name]">
<P>Depression was not a necessary inclusion criterion</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-04-25 11:44:07 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wellisch-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-04-25 11:44:07 +0100" MODIFIED_BY="[Empty name]">
<P>Could not confirm whether depression was a necessary inclusion criterion</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2010-01-21 14:18:09 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2013-04-07 12:27:09 +0100" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2013-04-07 12:27:09 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2013-04-07 12:27:09 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2013-04-07 12:27:09 +0100" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2013-04-07 12:27:09 +0100" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2013-04-07 12:27:09 +0100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2013-04-07 12:27:09 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2013-04-07 12:27:09 +0100" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES"/>
<FIGURES/>
<FEEDBACK/>
<APPENDICES MODIFIED="2013-04-29 12:59:24 +0100" MODIFIED_BY="Gail Quinn">
<APPENDIX ID="APP-01" MODIFIED="2013-04-25 11:44:07 +0100" MODIFIED_BY="Gail Quinn" NO="1">
<TITLE MODIFIED="2009-09-10 14:16:05 +0100" MODIFIED_BY="[Empty name]">MEDLINE search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2013-04-25 11:44:07 +0100" MODIFIED_BY="Gail Quinn">
<P>Conducted 22 July 2009</P>
<P>Ovid MEDLINE (R) In-Process &amp; Other Non-Indexed Citations and Ovid MEDLINE (R) 1950 to present (July week 2 2009)</P>
<P>1. exp depressive disorder/~<BR/>2. *Depressive Disorder, Major/<BR/>3. *Dysthymic Disorder/<BR/>4. Depression, involutional.mp.<BR/>5. Depress$.ab,ti.<BR/>6. Affective disorder$.ab,ti.<BR/>7. Mood disorder$.ab,ti.<BR/>8. 1 or 2 or 3 or 4 or 5 or 6 or 7<BR/>9. exp Glioma/<BR/>10. exp Brain Neoplasms/<BR/>11. brain tumo$.ab,ti.<BR/>12. astrocytoma$.ab,ti.<BR/>13. meningioma$.ab,ti.<BR/>14. oligodendroglioma$.ab,ti.<BR/>15. glioblastoma$.ab,ti.<BR/>16. 9 or 10 or 11 or 12 or 13 or 14 or 15<BR/>17. exp Antidepressive Agents/<BR/>18. exp Serotonin Uptake Inhibitors/<BR/>19. exp Monoamine Oxidase Inhibitors/<BR/>20. exp Drug Therapy/<BR/>21. Antidepress$.ab,ti.<BR/>22. TCA$.ab,ti.<BR/>23. Tricyclic$.ab,ti.<BR/>24. MAOI$.ab,ti.<BR/>25. SSRI$.ab,ti.<BR/>26. Antidepressive Agents, Tricyclic/<BR/>27. Antidepressive Agents, Second Generation/<BR/>28. 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27<BR/>29. 8 and 16 and 28<BR/>30. (animals not (humans and animals)).sh.<BR/>31. 29 not 30</P>
<P>(n = 57)</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2013-04-25 11:44:07 +0100" MODIFIED_BY="Gail Quinn" NO="2">
<TITLE MODIFIED="2009-09-10 14:18:41 +0100" MODIFIED_BY="[Empty name]">EMBASE search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2013-04-25 11:44:07 +0100" MODIFIED_BY="Gail Quinn">
<P>Conducted 22 July 2009</P>
<P>EMBASE 1980 to 2009 Week 29</P>
<P>1. exp Depression/<BR/>2. exp Mood Disorder/<BR/>3. "Depress*".ti,ab.<BR/>4. "Affect*".ti,ab.<BR/>5."Dysthym*".ti,ab.<BR/>6. 1 or 2 or 3 or 4 or 5<BR/>7. exp Glioma/<BR/>8. exp Brain Tumor/<BR/>9. Astrocytoma/<BR/>10.Meningioma/<BR/>11. (glioma* or brain tumo* or astrocytoma* or meningioma*).ti,ab.<BR/>12. 7 or 8 or 9 or 10 or 11<BR/>13. exp Antidepressant Agent/<BR/>14. Monoamine Oxidase Inhibitor/<BR/>15. Tricyclic Antidepressant Agent/<BR/>16. Serotonin Uptake Inhibitor/<BR/>17. (antidepress* or SSRI* or MAOI* or TCA* or tricyclic*).ti,ab.<BR/>18. 13 or 14 or 15 or 16 or 17<BR/>19. animal.sh<BR/>20. human.sh<BR/>21. 19 not (19 and 20)<BR/>22. 6 and 12 and 18<BR/>23. 22 not 21</P>
<P>(n = 287)</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2013-04-25 11:44:07 +0100" MODIFIED_BY="Gail Quinn" NO="3">
<TITLE MODIFIED="2009-09-10 14:38:09 +0100" MODIFIED_BY="[Empty name]">PsycINFO search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2013-04-25 11:44:07 +0100" MODIFIED_BY="Gail Quinn">
<P>Searched 22 July 2009</P>
<P>PsycINFO 1806 to July Week 2 2009</P>
<P>1. exp Endogenous Depression/<BR/>2. exp Reactive Depression/<BR/>3. exp Major Depression/<BR/>4. exp Mental Disorders/<BR/>5. exp Affective Disorders/<BR/>6. (depress$ or mood$ or affective$ or dysthym$).ab,ti.<BR/>7. 1 or 2 or 3 or 4 or 5 or 6<BR/>8. exp Brain Neoplasms/<BR/>9. brain tumo?r.mp.<BR/>10. Oligodendroglioma$.mp.<BR/>11. Astrocytoma$.mp.<BR/>12. Meningioma$.mp.<BR/>13. (glioma$ or brain tumo$ or astrocytoma$ or meningioma$ or oligodendroglioma$).ab,ti.<BR/>14. 8 or 9 or 10 or 11 or 12 or 13<BR/>15. exp Drug Therapy/<BR/>16. pharmacotherapy.mp.<BR/>17. exp Antidepressant Drugs/<BR/>18. exp Tricyclic Antidepressant Drugs/<BR/>19. exp Monoamine Oxidase Inhibitors/<BR/>20. exp Serotonin Reuptake Inhibitors/<BR/>21. (antidepress$ or SSRI$ or MAOI$ or TCA$ or tricyclic$ or drug therap$ or pharmacotherap$).ab,ti.<BR/>22.15 or 16 or 17 or 18 or 19 or 20 or 21<BR/>23. 7 and 14 and 22</P>
<P>(n = 39)</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-04" MODIFIED="2013-04-25 11:44:07 +0100" MODIFIED_BY="Gail Quinn" NO="4">
<TITLE MODIFIED="2009-09-10 14:49:37 +0100" MODIFIED_BY="[Empty name]">British Nursing Index search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2013-04-25 11:44:07 +0100" MODIFIED_BY="Gail Quinn">
<P>Searched 22 July 2009</P>
<P>British Nursing Index and Archive 1985 to July 2009</P>
<P>1. exp depression/<BR/>2. exp psychiatric disorders/<BR/>3. (depress$ or mood$ or affectiv$ or dysthym$).ti,ab.<BR/>4. 1 or 2 or 3<BR/>5. exp cancer/<BR/>6. (glioma$ or brain tumo$ or astrocytoma$ or meningioma$ or oligodendroglioma$).ti,ab.<BR/>7. 5 or 6<BR/>8. exp Drug Therapy/<BR/>9. exp Psychiatroc disorders : Drug Therapy/<BR/>10. SSRI$.mp.<BR/>11. MAOI$.mp.<BR/>12. Tricyclic.mp.<BR/>13. (antidepress$ or SSRI$ or MAOI$ or TCA$ or drug therap$ or pharmacotherap$).ti,ab.<BR/>14. 8 or 9 or 10 or 11 or 12 or 13<BR/>15. 4 and 7 and 14</P>
<P>(n = 20)</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-05" MODIFIED="2013-04-25 11:44:07 +0100" MODIFIED_BY="Gail Quinn" NO="5">
<TITLE MODIFIED="2009-09-10 14:55:29 +0100" MODIFIED_BY="[Empty name]">CENTRAL search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2013-04-25 11:44:07 +0100" MODIFIED_BY="Gail Quinn">
<P>Searched 22 July 2009</P>
<P>EBM Reviews - Cochrane Central Register of Controlled Trials 3rd Quarter 2009</P>
<P>1. Glioma/<BR/>2. exp Brain Neoplasms/<BR/>3. Astrocytoma/<BR/>4. Meningioma/<BR/>5. glioma.ti,kw,ab.<BR/>6. brain tumo$.ti,kw,ab.<BR/>7. astrocytoma$.ti,kw,ab.<BR/>8. meningioma$.ti,kw,ab.<BR/>9. oligodendroglioma$.ti,kw,ab.<BR/>10. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9<BR/>11. exp Antidepressive Agents/<BR/>12. exp Antidepressive Agents, Second-Generation/<BR/>13. Antidepressive Agents, Tricyclic/<BR/>14. Serotonin Uptake Inhibitors/<BR/>15. Monoamine Oxidase Inhibitors/<BR/>16. Antidepress$.ti,kw,ab.<BR/>17. SSRI$.ti,kw,ab.<BR/>18. MAOI$.ti,kw,ab.<BR/>19. TCA$.ti,kw,ab.<BR/>20. drug therap$.ti,kw,ab.<BR/>21. exp Drug Therapy/<BR/>22. pharmacotherapy.mp.<BR/>23. 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22<BR/>24. exp Mental Disorder/<BR/>25. Depression/<BR/>26. Affective Symptoms/<BR/>27. depress$.ti,kw,ab.<BR/>28. mood$.ti,kw,ab.<BR/>29. affectiv$.ti,kw,ab.<BR/>30. dysthym$.ti,kw,ab.<BR/>31. 24 or 25 or 26 or 27 or 28 or 29 or 30<BR/>32. 10 and 23 and 31</P>
<P>(n = 8)</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-06" MODIFIED="2013-04-25 11:44:07 +0100" MODIFIED_BY="[Empty name]" NO="6">
<TITLE MODIFIED="2009-09-10 15:08:47 +0100" MODIFIED_BY="[Empty name]">LILACS search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2013-04-25 11:44:07 +0100" MODIFIED_BY="[Empty name]">
<P>Searched 22 July 2009</P>
<P>1. Depression OR Depressive OR Mood OR Affect<BR/>2. Glioma OR Glioblastoma OR Meningioma OR Brain neoplasm<BR/>3. Antidepressant OR Antidepressive OR SSRI OR MAOI OR TCA<BR/>4. 1 and 2 and 3</P>
<P>(n = 0)</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-07" MODIFIED="2013-04-25 11:44:07 +0100" MODIFIED_BY="Gail Quinn" NO="7">
<TITLE MODIFIED="2009-09-10 15:10:52 +0100" MODIFIED_BY="[Empty name]">PSYNDEX search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2013-04-25 11:44:07 +0100" MODIFIED_BY="Gail Quinn">
<P>Searched 22 July 2009</P>
<P>(all search terms free text)</P>
<P>1. Depression OR Depressive OR Mood OR Affectiv?<BR/>2. Gliom? OR gehirntumo? OR Krebs OR Astrocytom? Or Oligodendrogliom? OR Meningiom?<BR/>3. Antidepress OR Serotonin OR SSRI OR MAOI OR TCA OR Pharmacotherap?<BR/>4. 1 and 2 and 3</P>
<P>(n = 1)</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-08" MODIFIED="2013-04-25 11:44:07 +0100" MODIFIED_BY="[Empty name]" NO="8">
<TITLE MODIFIED="2009-09-10 15:14:37 +0100" MODIFIED_BY="[Empty name]">National Research Register archive search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2013-04-25 11:44:07 +0100" MODIFIED_BY="[Empty name]">
<P>Searched 22 July 2009</P>
<P>(Database was only active until 2007)</P>
<P>1. "Glioma"</P>
<P>(n = 272)</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-09" MODIFIED="2013-04-25 11:44:07 +0100" MODIFIED_BY="Gail Quinn" NO="9">
<TITLE MODIFIED="2009-09-10 15:15:58 +0100" MODIFIED_BY="[Empty name]">DARE search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2013-04-25 11:44:07 +0100" MODIFIED_BY="Gail Quinn">
<P>Searched 22 July 2009</P>
<P>Database of Abstracts of Reviews of Effectiveness 3rd Quarter 2009</P>
<P>1. depress$.ab,ti.<BR/>2. affective disorder$.ab,ti.<BR/>3. mood disorder$.ab,ti.<BR/>4. 1 or 2 or 3<BR/>5. brain tumo$.ab,ti.<BR/>6. astrocytoma$.ab,ti.<BR/>7. meningioma$.ab,ti.<BR/>8. oligodendroglioma$.ab,ti.<BR/>9. glioblastoma$.ab,ti.<BR/>10. 5 or 6 or 7 or 8 or 9<BR/>11. antidepress$.ab,ti.<BR/>12. TCA$.ab,ti.<BR/>13. Tricyclic$.ab,ti.<BR/>14. MAOI$.ab,ti.<BR/>15. SSRI$.ab,ti.<BR/>16. 11 or 12 or 13 or 14 or 15<BR/>17. 4 and 10 and 16</P>
<P>(n = 0)</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-10" MODIFIED="2013-04-25 11:44:07 +0100" MODIFIED_BY="[Empty name]" NO="10">
<TITLE MODIFIED="2009-09-10 15:21:13 +0100" MODIFIED_BY="[Empty name]">Web of Knowledge search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2013-04-25 11:44:07 +0100" MODIFIED_BY="[Empty name]">
<P>Searched 22 July 2009</P>
<P>www.isiknowledge.com</P>
<P>Topic=(depression OR depressive disorder OR major depression OR mood disorder OR depress* OR affectiv* OR dysthym* OR mood*) AND Topic=(antidepress* OR SSRI OR MAOI OR TCA) AND Topic=(brain neoplas* OR brain tumo* OR glioma OR astrocytoma OR oligodendroglioma OR meningioma)</P>
<P>(n = 306)</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-11" MODIFIED="2013-04-29 12:59:14 +0100" MODIFIED_BY="[Empty name]" NO="11">
<TITLE MODIFIED="2013-04-07 12:42:39 +0100" MODIFIED_BY="[Empty name]">MEDLINE updated search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2013-04-29 12:59:14 +0100" MODIFIED_BY="[Empty name]">
<P>Searched to October 2012</P>
<P>1 exp Depressive Disorder/<BR/>2 Depression/<BR/>3 exp Mood Disorders/<BR/>4 depress*.mp.<BR/>5 ((affective or mood) adj disorder*).mp.<BR/>6 1 or 2 or 3 or 4 or 5<BR/>7 exp Brain Neoplasms/<BR/>8 exp Glioma/<BR/>9 (brain adj5 (tumor* or tumour* or neoplas* or malignan* or cancer* or carcinoma*)).mp.<BR/>10 (glioma* or astrocytoma* or meningioma* or oligodendroglioma* or glioblastoma*).mp.<BR/>11 7 or 8 or 9 or 10<BR/>12 drug therapy.fs.<BR/>13 exp Antidepressive Agents/<BR/>14 exp Serotonin Uptake Inhibitors/<BR/>15 exp Monoamine Oxidase Inhibitors/<BR/>16 (SSRI* or TCA* or MAOI* or tricyclic* or antidepress* or anti-depress*).mp.<BR/>17 12 or 13 or 14 or 15 or 16<BR/>18 6 and 11 and 17</P>
<P>(n = 45)</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-12" MODIFIED="2013-04-29 12:59:20 +0100" MODIFIED_BY="[Empty name]" NO="12">
<TITLE MODIFIED="2013-04-07 12:44:57 +0100" MODIFIED_BY="[Empty name]">EMBASE updated search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2013-04-29 12:59:20 +0100" MODIFIED_BY="[Empty name]">
<P>Searched to October 2012</P>
<P>1 exp mood disorder/<BR/>2 depress*.mp.<BR/>3 ((affective or mood) adj disorder).mp.<BR/>4 1 or 2 or 3<BR/>5 exp brain tumor/<BR/>6 exp glioma/<BR/>7 (brain adj5 (tumor* or tumour* or neoplas* or malignan* or cancer* or carcinoma*)).mp.<BR/>8 (glioma* or astrocytoma* or meningioma* or oligodendroglioma* or glioblastoma*).mp.<BR/>9 5 or 6 or 7 or 8<BR/>10 dt.fs.<BR/>11 exp antidepressant agent/<BR/>12 (SSRI* or TCA* or MAOI* or tricyclic* or antidepress* or anti-depress*).mp.<BR/>13 10 or 11 or 12<BR/>14 4 and 9 and 13</P>
<P>(n = 536)</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-13" MODIFIED="2013-04-16 10:58:44 +0100" MODIFIED_BY="[Empty name]" NO="13">
<TITLE MODIFIED="2013-04-07 12:46:14 +0100" MODIFIED_BY="[Empty name]">PsycINFO updated search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2013-04-16 10:58:44 +0100" MODIFIED_BY="[Empty name]">
<P>Searched October 2012</P>
<P>1 exp affective disorders/<BR/>2 depress*.mp.<BR/>3 ((affective or mood) adj disorder*).mp.<BR/>4 1 or 2 or 3<BR/>5 brain neoplasms/<BR/>6 glioma/<BR/>7 (brain adj5 (tumor* or tumour* or neoplas* or malignan* or cancer* or carcinoma*)).mp.<BR/>8 (glioma* or astrocytoma* or meningioma* or oligodendroglioma* or glioblastoma*).mp.<BR/>9 5 or 6 or 7 or 8<BR/>10 exp drug therapy/<BR/>11 exp antidepressant drugs/<BR/>12 exp Serotonin Reuptake Inhibitors/<BR/>13 exp Monoamine Oxidase Inhibitors/<BR/>14 (SSRI* or TCA* or MAOI* or tricyclic* or antidepress* or anti-depress*).mp.<BR/>15 10 or 11 or 12 or 13 or 14<BR/>16 4 and 9 and 15</P>
<P>(n = 17)</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-14" MODIFIED="2013-04-29 12:59:24 +0100" MODIFIED_BY="[Empty name]" NO="14">
<TITLE MODIFIED="2013-04-07 12:46:57 +0100" MODIFIED_BY="[Empty name]">CENTRAL updated search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2013-04-29 12:59:24 +0100" MODIFIED_BY="[Empty name]">
<P>Searched to October 2012</P>
<P>#1 MeSH descriptor: [Depressive Disorder] explode all trees<BR/>#2 MeSH descriptor: [Depression] explode all trees<BR/>#3 MeSH descriptor: [Mood Disorders] explode all trees<BR/>#4 depress*<BR/>#5 (affective or mood) near disorder*<BR/>#6 #1 or #2 or #3 or #4 or #5<BR/>#7 MeSH descriptor: [Brain Neoplasms] explode all trees<BR/>#8 MeSH descriptor: [Glioma] explode all trees<BR/>#9 brain near/5 (tumor* or tumour* or neoplas* or malignan* or cancer* or carcinoma*)<BR/>#10 glioma* or astrocytoma* or meningioma* or oligodendroglioma* or glioblastoma*<BR/>#11 #7 or #8 or #9 or #10<BR/>#12 Any MeSH descriptor with qualifier(s): [Drug therapy - DT] in all MeSH products<BR/>#13 MeSH descriptor: [Antidepressive Agents] explode all trees<BR/>#14 MeSH descriptor: [Serotonin Uptake Inhibitors] explode all trees<BR/>#15 MeSH descriptor: [Monoamine Oxidase Inhibitors] explode all trees<BR/>#16 SSRI* or TCA* or MAOI* or tricyclic* or antidepress* or anti-depress*<BR/>#17 #12 or #13 or #14 or #15 or #16<BR/>#18 #6 and #11 and #17</P>
<P>(n = 6)</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>